RGD Reference Report - Vasoactive intestinal polypeptide, an erectile neurotransmitter, improves erectile function more significantly in castrated rats than in normal rats. - Rat Genome Database

RGD Reference Report - Vasoactive intestinal polypeptide, an erectile neurotransmitter, improves erectile function more significantly in castrated rats than in normal rats. - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

General

Vasoactive intestinal polypeptide, an erectile neurotransmitter, improves erectile function more significantly in castrated rats than in normal rats.
Authors:	Zhang, MG Shen, ZJ Zhang, CM Wu, W Gao, PJ Chen, SW Zhou, WL
Citation:	Zhang MG, etal., BJU Int. 2011 Aug;108(3):440-6. doi: 10.1111/j.1464-410X.2010.09901.x. Epub 2010 Dec 16.
RGD ID:	5685628
Pubmed:	PMID:21166748 (View Abstract at PubMed)
DOI:	DOI:10.1111/j.1464-410X.2010.09901.x (Journal Full-text)
OBJECTIVE: * To investigate the regulatory role of androgen in VIP-mediated erectile effect. Androgen is essential for physiological erection. Vasoactive intestinal polypeptide (VIP) is an important erectile neurotransmitter. While previous studies demonstrated that VIP expression in the penis was androgen-independent, it remains controversial whether androgen has any effect on VIP-mediated erection. MATERIALS AND METHODS: * Male SD rats were divided into a control group, a castration group, and a castration-with-testosterone-replacement group. Four weeks later, each group was subdivided into low and high-dose VIP subgroups and subjected to intracavernous injection of 0.5 and 2 microg VIP, respectively. * Erectile function was tested by recording intracavernosal pressure (ICP) and mean arterial blood pressure (MAP) before and after VIP injection. * The expressions of the VIP-receptor (VPAC2), G-protein stimulatory and inhibitory alpha subunits (Gs-alpha, Gi-alpha), and PDE3A in rat corpus cavernosum (CC) was qualified by real-time PCR and Western blot analysis. RESULTS: * Castration reduced erectile function while testosterone restored it. VIP improved erectile function in a dose-dependent manner. * High-dose VIP significantly enhanced erectile function in castrated rats and there was no difference of ICP/MAP among three groups after injection of high-dose VIP. * Low-dose VIP also resulted in a higher improvement of erectile function in castrated rats, although the ICP/MAP was lower in these rats than in the other two groups. VPAC2 and Gs-alpha were up-regulated while Gi-alpha and PDE3A were down-regulated in CC of castrated rats. CONCLUSION: * VIP improves erectile function much more significantly in hypogonadal condition, mainly due to the higher expression of VPAC2, Gs-alpha, and lower expression of Gi-alpha and PDE3A in CC of castrated rats. Androgen may negatively regulate the erectile effect of VIP.

Annotation Click to see Annotation Detail View

Gene Ontology Annotations Click to see Annotation Detail View

Biological Process

Only show annotations with direct experimental evidence (0 objects hidden)

Object Symbol	Species	Term	Qualifier	Evidence	With	Notes	Source	Original Reference(s)
Vip	Rat	positive regulation of penile erection		IDA			RGD

Objects Annotated

Genes (Rattus norvegicus)

Vip (vasoactive intestinal peptide)

Additional Information